79 / 89
79
84.
Mercado U, Arroyo de Anda R, Avendaño L,
Araiza-Casillas
R,
Avendaño-Reyes
M.
Metoclopramide response in patients with early
diffuse systemic sclerosis. Effects on esophageal
motility abnormalities. Clin Exp Rheumatol
2005;23:685-8.
85.
Johnson DA, Drane WE, Curran J, Benjamin SB,
Chobanian SJ, Karvelis K, et al. Metoclopramide
response in patients with progressive systemic
sclerosis. Effect on esophageal and gastric
motility abnormalities. Arch Intern Med
1987;147:1597-601.
86.
Nikou GC, Toumpanakis C, Katsiari C,
Charalambopoulos D, Sfikakis PP. Treatment of
small intestinal disease in systemic sclerosis
with octreotide: a prospective study in seven
patients. J Clin Rheumatol 2007;13:119-23.
87.
Verne GN, Eaker EY, Hardy E, Sninsky CA.
Effect of octreotide and erythromycin on
idiopathic and scleroderma-associated intestinal
pseudoobstruction. Dig Dis Sci 1995;40:1892-
901.
88.
Marie I, Dominique S, Levesque H, Ducrotté P,
Denis P, Hellot MF, et al. Esophageal
involvement and pulmonary manifestations in
systemic sclerosis. Arthritis Rheum 2001;45:346-
54.
89.
Janiak P, Thumshirn M, Menne D, Fox M, Halim
S, Fried M, et al. Clinical trial: the effects of
adding ranitidine at night to twice daily
omeprazole therapy on nocturnal acid